Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

47.07 +0.06 (+0.13%)
Streaming Delayed Price Updated: 10:40 AM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Friday's session: top gainers and losers in the S&P500 index
Curious about the S&P500 stocks that are in motion on Friday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Europe Approves Bristol Myers' Cell Therapy Breyanzi For Patients With Certain Type Of Blood Cancer
EC approves BMY's Breyanzi for relapsed or refractory FL, based on Phase 2 study showing high response rates & sustained efficacy. 
Via Benzinga
These S&P500 stocks are gapping in today's session
Looking for opportunities in today's market? Check out the S&P500 gap up and gap down stocks on Friday and stay ahead of the market trends. 
Via Chartmill
Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Follicular Lymphoma
From Bristol Myers Squibb
Via Business Wire
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Perspective Therapeutics' Cancer-Focused Radiotherapy Portfolio Has Upside Potentional, Says Analyst
H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets. 
Via Benzinga
Bristol Myers Squibb to Report Results for First Quarter 2025 on April 24, 2025
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb Co Chart Analysis
Technical analysis of the stock chart for BMY. 
Via Talk Markets
Topics Stocks / Equities
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 2seventy bio, Inc. (Nasdaq - TSVT), Bridge Investment Group Holdings Inc. (NYSE - BRDG), Chimerix, Inc. (Nasdaq - CMRX), 180 Degree Capital Corp. (Nasdaq – TURN)
From Brodsky & Smith LLC
Via GlobeNewswire
Is NYSE:BMY suited for dividend investing?
Analyzing BRISTOL-MYERS SQUIBB CO (NYSE:BMY)'s Dividend Potential. 
Via Chartmill
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Scoops Up Its Blood Cancer Drug Partner 2seventy Bio In $286 Million Deal
Bristol Myers Squibb to acquire 2seventy Bio for $5.00 per share in a $286 million all-cash deal, an 88% premium to its last close. Expected to close in Q2 2025. 
Via Benzinga
US Stocks Likely To Open Higher After Monday's Selloff: TSLA Stock Rebounds From Its Worst Fall In 5 Years After Trump Backs Musk, Analyst Says 'Pullbacks Are Normal'
U.S. stock futures rose on Tuesday following Monday's heavy selloff. Futures of all four benchmark indices surged in premarket trading. 
Via Benzinga
Topics Government
Which S&P500 stocks are moving on Monday?
Curious about the S&P500 stocks that are in motion on Monday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Bristol Myers Unveils Positive Phase 3 Results for Sotyktu in Psoriatic Arthritis
Bristol Myers Squibb's Phase 3 POETYK PsA-2 trial shows Sotyktu improved psoriatic arthritis symptoms, meeting primary and secondary endpoints at Week 16. 
Via Benzinga
Why Is Protagonist Therapeutics Stock Trading Higher On Monday?
Protagonist and Johnson & Johnson's treatment for ulcerative colitis and psoriasis studies met key endpoints. 
Via Benzinga
Protagonist Therapeutics Unveils 'Paradigm-Shifting' Drug And Breaks Out
The company is looking to take on Bristol Myers Squibb's Sotyktu in plaque psoriasis treatment. 
Via Investor's Business Daily
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Healthcare Sector Trying To Bounce Back
I often discuss highly rated stocks that are part of highly rated sectors. Thus, this time is a departure from the norm. Let's dive into the data for the healthcare sector. 
Via Talk Markets
Topics ETFs Stocks / Equities
Bristol Myers Squibb Presents Late-Breaking Data from Phase 3 POETYK PsA-2 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' Opdivo Plus Yervoy Combo Therapy Secures European Approval For Untreated Liver Cancer Patients
The European Commission approved Opdivo plus Yervoy for first-line treatment of advanced liver cancer, citing significant overall survival benefits. 
Via Benzinga
Bristol Myers Squibb Receives European Commission Approval for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) for the First-Line Treatment of Adult Patients with Unresectable or Advanced Hepatocellular Carcinoma
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Acquired MyoKardia Drops Fulcrum Agreement, Ending Cardiomyopathy Research Deal
MyoKardia, a Bristol Myers unit, is terminating its agreement with Fulcrum Therapeutics, ending a cardiomyopathy research deal set to expire in June 2025. 
Via Benzinga
Branded Pharmaceuticals Stocks Q4 In Review: Bristol-Myers Squibb (NYSE:BMY) Vs Peers
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb (BMY): Buy, Sell, or Hold Post Q4 Earnings?
Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, representing a healthy 18.8% increase. This run-up might have... 
Via StockStory
Topics Stocks
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.